Scarica l'app Stockscreener
0.9124
1.04%
0.0094
Dopo l'orario di chiusura:
.93
0.0176
+1.93%
Precedente Chiudi:
$0.903
Aprire:
$0.9
Volume 24 ore:
265.36K
Relative Volume:
0.61
Capitalizzazione di mercato:
$65.96M
Reddito:
$208.60K
Utile/perdita netta:
$-58.59M
Rapporto P/E:
-0.9956
EPS:
-0.9164
Flusso di cassa netto:
$-47.11M
1 W Prestazione:
-1.89%
1M Prestazione:
-0.84%
6M Prestazione:
-33.88%
1 anno Prestazione:
-20.66%
Intervallo 1D:
$0.8626
$0.9399
Intervallo di 1 settimana:
$0.8007
$0.9595
Portata 52W:
$0.7113
$1.94
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.9124 | 65.96M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-02-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-04-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-01-29 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-10 | Iniziato | Credit Suisse | Outperform |
| 2018-07-13 | Iniziato | BMO Capital Markets | Outperform |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-28 | Iniziato | SunTrust | Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Inflarx N V Borsa (IFRX) Ultime notizie
InflaRx NV stock: Biotech innovator or high-risk bet? - AD HOC NEWS
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP - TipRanks
InflaRx (NASDAQ: IFRX) 2026 AGM to expand share pool, renew buyback - Stock Titan
IFRX Technical Analysis & Stock Price Forecast - Intellectia AI
InflaRx N : Long-term Incentive Plan “LTIP 2026” (LTIP 2026 FINAL) - MarketScreener
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - bitget.com
IFRX Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
InflaRx presents phase 3 vilobelimab data at dermatology meeting By Investing.com - Investing.com India
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - Bitget
InflaRx presents phase 3 vilobelimab data at dermatology meeting - Investing.com
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Sell Signal: Can InflaRx NV deliver consistent dividends2026 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Treasury Yields: Can InflaRx NV sustain earnings growth2026 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Can InflaRx's Vilobelimab Stage A Revival In Pyoderma Gangrenosum? - RTTNews
HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
Analyst Upgrade: Is InflaRx NV a top pick in the sector2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Aug Shorts: Can InflaRx NV sustain earnings growthMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
Bear Alert: Is InflaRx NV a top pick in the sector2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
InflaRx NV (IFRX) reports Q4 loss, lags revenue estimates - MSN
Raymond James raises Inflarx stock price target on drug trial data - Investing.com India
Raymond James raises Inflarx stock price target on drug trial data By Investing.com - Investing.com South Africa
InflaRx Survival Hopes Rest On Izicopan - Citeline News & Insights
InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim - MarketBeat
Guggenheim cuts Inflarx stock price target on model update to $14 By Investing.com - Investing.com South Africa
Guggenheim cuts Inflarx stock price target on model update to $14 - Investing.com Canada
Q1 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
InflaRx (IFRX) posts 2025 loss, relies on cash runway and grants - Stock Titan
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Meets Expectations - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
Inflarx reports full year 2025 results and highlights key achievements and expected milestones - marketscreener.com
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
After focusing on izicopan, InflaRx says cash lasts until mid-2027 - Stock Titan
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
InflaRx FY 2025 earnings preview - MSN
InflaRx N.V. (IFRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Aug Opening: Is InflaRx NV forming bullish engulfing patterns2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Aug Levels: Can InflaRx NV outperform under higher oil prices2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
InflaRx (IFRX) director Mark Kubler reports 960,015 shares and multiple options - Stock Titan
InflaRx (IFRX) director lists options and 10,000 Ordinary Shares - Stock Titan
InflaRx (IFRX) director Brudnick reports shares and multiple stock option grants - stocktitan.net
InflaRx (IFRX) director details vested and future stock options - Stock Titan
InflaRx (IFRX) CSO discloses 1.76M shares and multiple option grants - Stock Titan
InflaRx (IFRX) officer discloses vested and performance stock options - stocktitan.net
InflaRx (IFRX) director discloses sizeable share and option stakes - Stock Titan
Inflarx N V Azioni (IFRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):